Career records & work history
Medicine Doctors
Jennifer Ann Schranz
Specialties:
Internal Medicine
Infectious Disease
Infectious Disease
Education:
University Of Toronto Faculty Of Medicine (1989)
Jennifer Ann Schranz, 601300 Sugartown Rd, Berwyn, PA 19312
Jennifer Schranz Phones & Addresses
1300 Sugartown Rd, Berwyn, PA 19312 610-4892093
1221 Sugarberry Ln, Collegeville, PA 19426 610-4092651
Newport, PA
Westborough, MA
51 Goldfinch Cir, Phoenixville, PA 19460
Calverton, NY
Coram, NY
1221 Sugarberry Ln, Collegeville, PA 19426
Work
Position:
Service Occupations
Education
Degree:
Graduate or professional degree
Emails
Mentions for Jennifer Ann Schranz
Jennifer Schranz resumes & CV records
Resumes
Chief Marketing Officer
Location:
Collegeville, PA
Industry:
Biotechnology
Work:
Nabriva Therapeutics Plc
Chief Marketing Officer Shire
Vice President Clinical Development
Chief Marketing Officer Shire
Vice President Clinical Development
Education:
University of Toronto
Assistant Vice President
Location:
Collegeville, PA
Industry:
Pharmaceuticals
Work:
Wyeth Vaccines
2005 - 2010
Global Therapeutic Area Director Pfizer 2005 - 2010
Assistant Vice President Pfizer 2005 - 2010
Avp, Global Therapeutic Area Director Vicuron Pharmaceuticals 2001 - 2004
Senior Director Merck 1996 - 2001
Director
Global Therapeutic Area Director Pfizer 2005 - 2010
Assistant Vice President Pfizer 2005 - 2010
Avp, Global Therapeutic Area Director Vicuron Pharmaceuticals 2001 - 2004
Senior Director Merck 1996 - 2001
Director
Publications & IP owners
Us Patents
Plasma Kallikrein Inhibitors And Uses Thereof For Treating Hereditary Angioedema Attack
US Patent:
2018036, Dec 20, 2018
Filed:
Dec 9, 2016
Appl. No.:
16/061103
Inventors:
- Lexington MA, US
Yung Chyung - Lexington MA, US
Jennifer Schranz - Lexington MA, US
Yung Chyung - Lexington MA, US
Jennifer Schranz - Lexington MA, US
Assignee:
Dyax Corp. - Lexington MA
International Classification:
C07K 16/40
A61K 39/395
A61P 29/00
A61K 39/395
A61P 29/00
Abstract:
Provided herein are plasma kallikrein antibodies binding to active plasma kallikrein and methods of using such antibodies in treating and preventing hereditary angioedema attack, such method may involve a first treatment period and optionally, a second treatment period. Also provided are methods of using such antibodies in treating hereditary angioedema involving a single dose of the antibody to a subject who has undergone a prior HAE treatment, followed by multiple doses of the same antibody if the subject experiences an HAE attack after the single dose.
NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.